A bispecific dsDNA × monoclonal antibody construct for clearance of anti-dsDNA IgG in systemic lupus erythematosus

Journal of Immunological Methods

Volumn 248, Issue 1-2, 2001, Pages 125-138

  Lindorfer, Margaret A ^a   Schuman, Theodore A ^a   Craig, Maria L ^a   Martin, Edward N ^a   Taylor, Ronald P ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Autoantibodies; Bispecific; Complement receptor 1; Systemic lupus erythematosus

Indexed keywords

AMMONIUM SULFATE; AUTOANTIBODY; DNA ANTIBODY; DYE; EUROPIUM; IMMUNOGLOBULIN G; PICOGREEN; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; BISPECIFIC ANTIBODY; COMPLEMENT COMPONENT C3B RECEPTOR; DNA; MONOCLONAL ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CROSS LINKING; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; DOSE RESPONSE; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM;

ANIMALIA;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; DNA; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ERYTHROCYTES; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, COMPLEMENT 3B;

EID: 0035241890     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00348-3     Document Type: Article

References (59)

1. Immunology of DNA. IV. Quantitative aspects of the Farr assay
2. Immunology of DNA. II. The effect of size and structure of the antigen on the Farr assay
3. Severe infections in plasmapheresis-treated systemic lupus erythematosus
4. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long term observation
5. Effect of antibody excess on the size, stoichiometry, and DNAse resistance of DNA anti-DNA immune complexes
6. Monoclonal antibodies to oncoproteins
7. Distribution in clusters of complement receptor type one (CR1) on human erythrocytes
8. Synthesis of an amplifiable reporter RNA for bioassays
9. Primate erythrocyte-immune complex-clearing mechanism
10. Clearance of anti-double-stranded DNA antibodies: The natural immune complex clearance mechanism
11. A study of in vivo immune complex formation and clearance in man
12. Immune complex processing in patients with systemic lupus erythematosus
13. Rapid immune adherence reactivity of nascent, soluble antibody/DNA immune complexes in the circulation
14. Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes
15. Quantitative analyses of the binding of soluble complement-fixing antibody/dsDNA immune complexes to CR1 on human red blood cells
16. DNA-anti-DNA immune complexes. Antibody protection of a discrete DNA fragment from DNAse protection in vitro
17. A new ELISA for the detection of double-stranded DNA antibodies
18. Antibodies to DNA. A perspective
19. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte
20. Antigen-based heteropolymers: A potential therapy for binding and clearing autoantibodies via erythrocyte CR1
21. Immune complexes in systemic lupus erythematosus
22. Use of maleimide-thiol coupling chemistry for efficient syntheses of oligonucleotide-enzyme conjugate hybridization probes
23. Selective absorption of anti-DNA antibodies and their idiotype-positive cells in vitro using an anti-idiotypic antibody-affinity column: Possible application to plasma exchange
24. Selective removal of anti-DNA and anticardiolipin antibodies by adsorbent plasmapheresis using dextran sulfate columns in patients with systemic lupus erythematosus
25. Europium as a label in time-resolved fluorometric assays
26. Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus
27. Selective removal of anti-double-stranded DNA antibodies by immunoadsorption with dextran sulfate in a patient with systemic lupus erythematosus
28. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs
29. Studies of the physical biochemistry and complement-fixing properties of DNA/anti-DNA immune complexes
30. A controlled trial of plasmapheresis therapy in severe lupus nephritis
31. Reassessment of the clinical significance of native DNA antibodies in systemic lupus erythematosus
32. A prototype pathogen bound ex vivo to human erythrocyte complement receptor 1 via bispecific monoclonal antibody complexes is cleared to the liver in a mouse model
33. Direct evidence of the clustered nature of complement receptors type 1 on the erythrocyte membrane
34. Reaction of systemic lupus erythematosus antinative DNA antibodies with native DNA fragments from 20 to 1,200 base pairs
35. Cross-linked bispecific monoclonal antibody heteropolymers facilitate the clearance of human IgM from the circulation of squirrel monkeys
36. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation
37. Physiological and pathological aspects of circulating immune complexes
38. Immunoadsorbent plasma perfusion in patients with systemic lupus erythematosus
39. Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway
40. Production of bispecific antibodies
41. Reaction patterns of monoclonal antibodies to DNA
42. Anti-DNA antibodies
43. Continuous removal of anti-DNA antibody, using a new extracorporeal immunoadsorption system, in patients with systemic lupus erythematosus
44. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus
45. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus
46. Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology
47. Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus
48. The interaction of antibody/DNA immune complexes with complement. Influence of antibody class and DNA conformation
49. Primate erythrocyte (E) complement receptor (CR1) as an anchor site for bispecific-based therapies to clear pathogens or autoantibodies safely from the circulation
50. Bispecific monoclonal antibody complexes bound to primate erythrocyte CR1 facilitate virus clearance in a monkey model
51. Immune complexes bound to the primate erythrocyte complement receptor (CR1) via anti-CR1 mAbs are cleared simultaneously with loss of CR1 in a concerted reaction in a rhesus monkey model
52. Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: A potential therapeutic treatment
53. Murine models of systemic lupus erythematosus
54. A time-resolved immunofluorometric assay of autoantibodies to double-stranded DNA
55. Randomized trial of plasma exchange in mild systemic lupus erythematosus
56. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus